Esteban Porrini

List of Publications by Year
in descending order

87 papers	28,526 citations	159585 30 h-index	58581 82 g-index
92 all docs	92 docs citations	92 times ranked	46741 citing authors

#	Article	IF	Citations
1	Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus. Nephrology Dialysis Transplantation, 2022, 37, 1125-1131.	0.7	10
2	Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity. CKJ: Clinical Kidney Journal, 2022, 15, 885-894.	2.9	1
3	Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method. Journal of Nephrology, 2022, 35, 2109-2118.	2.0	3
4	Estimating Renal Function Following Lung Transplantation. Journal of Clinical Medicine, 2022, 11, 1496.	2.4	3
5	Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update. Nephron, 2021, 145, 317-329.	1.8	21
6	Renal histology across the stages of chronic kidney disease. Journal of Nephrology, 2021, 34, 699-707.	2.0	11
7	Iohexol plasma clearance simplified by Dried Blood Spot (DBS) sampling to measure renal function in conscious mice. Scientific Reports, 2021, 11, 4591.	3.3	7
8	Estimated GFR Slope in Kidney Transplant Patients. Transplantation, 2021, Publish Ahead of Print, .	1.0	3
9	Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury. American Journal of Physiology - Renal Physiology, 2021, 320, F628-F643.	2.7	15
10	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. Transplant International, 2021, 34, 1341-1359.	1.6	9
11	Obesity and metabolic syndrome induce hyperfiltration, glomerulomegaly, and albuminuria in obese ovariectomized female mice and obese male mice. Menopause, 2021, 28, 1296-1306.	2.0	6
12	Beta-Cell Dysfunction Induced by Tacrolimus: A Way to Explain Type 2 Diabetes?. International Journal of Molecular Sciences, 2021, 22, 10311.	4.1	17
13	The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease. Kidney International Reports, 2021, 6, 2392-2403.	0.8	9
14	Transforming growth factor Î²3 deficiency promotes defective lipid metabolism and fibrosis in murine kidney. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	11
15	Parenchymal biopsy in the management of patients with renal cancer. World Journal of Urology, 2021, 39, 2961-2968.	2.2	14
16	Renoprotective role of bariatric surgery in patients with established chronic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 2037-2046.	2.9	19
17	Exercise and Prediabetes after Renal Transplantation (EXPRED): Protocol Description. Nephron, 2021, 145, 55-62.	1.8	2
18	Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure. Liver International, 2021, , .	3.9	3

#	Article	IF	Citations
19	The Iberian pig fed with high-fat diet: a model of renal disease in obesity and metabolic syndrome. International Journal of Obesity, 2020, 44, 457-465.	3.4	20
20	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. Kidney International Reports, 2020, 5, 189-198.	0.8	13
21	The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. International Journal of Obesity, 2020, 44, 1129-1140.	3.4	41
22	A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease. Biology, 2020, 9, 259.	2.8	3
23	SGLT2i and postglomerular vasodilation. Kidney International, 2020, 97, 805-806.	5.2	4
24	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020, 9, 2030.	2.4	28
25	Dulaglutide slows kidney disease in type 2 diabetes. Lancet, The, 2020, 395, 559.	13.7	0
26	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. Kidney and Blood Pressure Research, 2020, 45, 166-179.	2.0	11
27	Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stressâ€“Activated FOXO1 to Trigger Î²-Cell Failure. Diabetes, 2020, 69, 193-204.	0.6	20
28	SAT-092 THE DUEL OF DAVID AND GOLIATH: HOW SHOULD MGFR BEAT THE ESTIMATED GFR?. Kidney International Reports, 2020, 5, S41-S42.	0.8	0
29	Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. Nephrology Dialysis Transplantation, 2019, 34, 287-294.	0.7	22
30	The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology. Nutrients, 2019, 11, 1748.	4.1	77
31	Prediabetes is a risk factor for cardiovascular disease following renal transplantation. Kidney International, 2019, 96, 1374-1380.	5.2	28
32	You Only Can Treat and Prevent What You Know. Nephron, 2019, 143, 1-2.	1.8	1
33	SP265THE ESTIMATION OF GFR AND THE ADJUSTMENT FOR BSA IN OVERWEIGHT AND OBESITY: A DREADFUL COMBINATION OF TWO ERRORS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	1
34	Response to â€œIohexol-measured glomerular filtration rate in children and adolescents with chronic kidney disease: a pilot study comparing venous and finger stick methodsâ€• Pediatric Nephrology, 2019, 34, 1629-1630.	1.7	0
35	The Error of Estimated GFR in Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 1543.	2.4	15
36	Reply to â€˜Strengths and limitations of estimated and measured GFRâ€™. Nature Reviews Nephrology, 2019, 15, 785-786.	9.6	5

#	Article	IF	Citations
37	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. CKJ: Clinical Kidney Journal, 2019, 12, 313-321.	2.9	35
38	Inhibition of the mTOR pathway: A new mechanism of Î² cell toxicity induced by tacrolimus. American Journal of Transplantation, 2019, 19, 3240-3249.	4.7	26
39	Impact of errors of creatinine and cystatin C equations in the selection of living kidney donors. CKJ: Clinical Kidney Journal, 2019, 12, 748-755.	2.9	14
40	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.7	147
41	Renal Disease in Obesity, Metabolic Syndrome and Diabesity. , 2019, , 65-80.		1
42	Estimated GFR: time for a critical appraisal. Nature Reviews Nephrology, 2019, 15, 177-190.	9.6	187
43	Iohexol plasma clearance simplified by dried blood spot testing. Nephrology Dialysis Transplantation, 2018, 33, 1597-1603.	0.7	29
44	SP432THE ERROR OF ESTIMATED GFR Y TYPE 2 DIABETES. Nephrology Dialysis Transplantation, 2018, 33, i493-i494.	0.7	0
45	FP107CKD STAGING WITH CYSTATINâ˜C OR CREATININEâ˜BASED FORMULAS: FLICKING THE COIN. Nephrology Dialysis Transplantation, 2018, 33, i13-i13.	0.7	7
46	Characterization of Ageing- and Diet-Related Swine Models of Sarcopenia and Sarcopenic Obesity. International Journal of Molecular Sciences, 2018, 19, 823.	4.1	12
47	A Simple Method to Measure Renal Function in Swine by the Plasma Clearance of Iohexol. International Journal of Molecular Sciences, 2018, 19, 232.	4.1	10
48	Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. Kidney International Reports, 2018, 3, 1304-1315.	0.8	47
49	Deciphering Tacrolimus-Induced Toxicity in Pancreatic Î² Cells. American Journal of Transplantation, 2017, 17, 2829-2840.	4.7	54
50	Evaluation of Renal Function and Renal Risk in the Twenty-First Century. Nephron, 2017, 136, 261-262.	1.8	1
51	An Overview of Errors and Flaws of Estimated GFR versus True GFR in Patients with Diabetes Mellitus. Nephron, 2017, 136, 287-291.	1.8	36
52	Renal Function Measurements. , 2017, , 419-427.		0
53	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. CKJ: Clinical Kidney Journal, 2016, 9, 682-699.	2.9	169
54	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. CKJ: Clinical Kidney Journal, 2016, 9, 700-704.	2.9	150

#	Article	IF	Citations
55	Iohexol plasma clearance, a simple and reliable method to measure renal function in conscious mice. Pflugers Archiv European Journal of Physiology, 2016, 468, 1587-1594.	2.8	13
56	Simplified Method to Measure Glomerular Filtration Rate by Iohexol Plasma Clearance in Conscious Rats. Nephron, 2016, 133, 62-70.	1.8	9
57	Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nature Reviews Nephrology, 2016, 12, 453-471.	9.6	461
58	Clinical evolution of post-transplant diabetes mellitus. Nephrology Dialysis Transplantation, 2016, 31, 495-505.	0.7	77
59	Estimated Glomerular Filtration Rate in Renal Transplantation. Transplantation, 2015, 99, 2625-2633.	1.0	30
60	Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2015, 3, 382-391.	11.4	168
61	Cambios en la homeostasis de la glucosa y la proliferaciÃ³n de la cÃ©lula beta pancreÃ¡tica tras el cambio a ciclosporina en la diabetes inducida por tacrolimus. Nefrologia, 2015, 35, 264-272.	0.4	9
62	Glucose homeostasis changes and pancreatic Î²-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus. Nefrologia, 2015, 35, 264-272.	0.4	9
63	Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes and Endocrinology,the, 2014, 2, 417-426.	11.4	355
64	Measurement of glomerular filtration rate: Internal and external validations of the iohexol plasma clearance technique by HPLC. Clinica Chimica Acta, 2014, 430, 84-85.	1.1	16
65	Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrology Dialysis Transplantation, 2013, 28, 550-566.	0.7	100
66	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney International, 2013, 84, 164-173.	5.2	131
67	The Higher Diabetogenic Risk of Tacrolimus Depends on Pre-Existing Insulin Resistance. A Study in Obese and Lean Zucker Rats. American Journal of Transplantation, 2013, 13, 1665-1675.	4.7	40
68	Reninâ€“angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrology Dialysis Transplantation, 2012, 27, 417-422.	0.7	37
69	Early Association of Low-Grade Albuminuria and Allograft Dysfunction Predicts Renal Transplant Outcomes. Transplantation, 2012, 93, 297-303.	1.0	26
70	Clinical Trials for Treatment of NODAT. Transplantation, 2012, 94, e23-e24.	1.0	10
71	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
72	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	13.7	11,038

#	Article	IF	Citations
73	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
74	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1717-1724.	6.1	80
75	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. Diabetes Care, 2012, 35, 2061-2068.	8.6	259
76	Is adiponectin a marker of preclinical atherosclerosis in kidney transplantation?. Clinical Transplantation, 2012, 26, 259-266.	1.6	7
77	Metabolic syndrome, insulin resistance, and chronic allograft dysfunction. Kidney International, 2010, 78, S42-S46.	5.2	25
78	Hyperinsulinemia and Hyperfiltration in Renal Transplantation. Transplantation, 2009, 87, 274-279.	1.0	9
79	Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant International, 2008, 21, 955-962.	1.6	27
80	Unmasking Glucose Metabolism Alterations in Stable Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 808-813.	4.5	22
81	Prediabetes in Patients Receiving Tacrolimus in the First Year After Kidney Transplantation: A Prospective and Multicenter Study. Transplantation, 2008, 85, 1133-1138.	1.0	60
82	Glycated haemoglobin levels are related to chronic subclinical inflammation in renal transplant recipients without pre-existing or new onset diabetes. Nephrology Dialysis Transplantation, 2007, 22, 1994-1999.	0.7	11
83	Time-dependent changes in cardiac growth after kidney transplantation: the impact of pre-dialysis ventricular mass. Nephrology Dialysis Transplantation, 2007, 22, 2678-2685.	0.7	33
84	The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrology Dialysis Transplantation, 2007, 23, 1436-1441.	0.7	62
85	Randomized Controlled Study Comparing Reduced Calcineurin Inhibitors Exposure Versus Standard Cyclosporine-Based Immunosuppression. Transplantation, 2007, 84, 706-714.	1.0	44
86	Carotid Atheromatosis in Nondiabetic Renal Transplant Recipients: The Role of Prediabetic Glucose Homeostasis Alterations. Transplantation, 2007, 84, 870-875.	1.0	15
87	Impact of Metabolic Syndrome on Graft Function and Survival After Cadaveric Renal Transplantation. American Journal of Kidney Diseases, 2006, 48, 134-142.	1.9	128